AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • October 18th, 2021 • PPD, Inc. • Services-commercial physical & biological research • New York
THIS AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is entered into as of the 6th day of October, 2021, by and among Science 37 Holdings, Inc., a Delaware corporation (f/k/a LifeSci Acquisition II Corp.) (the “Company”), the equityholders designated as Sponsor Equityholders on Schedule A hereto (collectively, the “Sponsor Equityholders”) and the equityholders designated as Legacy Science 37 Equityholders on Schedule B hereto (collectively, the “Legacy Science 37 Equityholders” and, together with the Sponsor Equityholders and any person or entity who hereafter becomes a party to this Agreement pursuant to Section 6.2 of this Agreement, each an “Investor” and collectively, the “Investors”).
PPD, INC. [●] Shares of Common Stock Underwriting AgreementPPD, Inc. • January 27th, 2020 • Services-commercial physical & biological research • New York
PPD, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of [●] shares of Common Stock, par value $0.01 per share, of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional [●] shares of Common Stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
AGREEMENT AND PLAN OF MERGER dated as of April 15, 2021, among THERMO FISHER SCIENTIFIC INC., POWDER ACQUISITION CORP. and PPD, INC.Agreement and Plan of Merger • April 16th, 2021 • PPD, Inc. • Services-commercial physical & biological research • Delaware
AGREEMENT AND PLAN OF MERGER dated as of April 15, 2021 (this “Agreement”), by and among Thermo Fisher Scientific Inc., a company organized under the laws of Delaware (“Parent”), Powder Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and PPD, Inc., a Delaware corporation (the “Company”). Unless expressly stated otherwise, Parent, Merger Sub and the Company are referred to in this Agreement individually as a “party” and collectively as the “parties”.
PPD, INC. [ • ] Shares of Common Stock Underwriting AgreementUnderwriting Agreement • September 14th, 2020 • PPD, Inc. • Services-commercial physical & biological research • New York
Certain stockholders named in Schedule 2 hereto (the “Selling Stockholders”) of PPD, Inc., a Delaware corporation (the “Company”), propose to sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of [ • ] shares of Common Stock, par value $0.01 per share, of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional [ • ] shares of Common Stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
EAGLE HOLDING COMPANY II, LLC as Issuer 7.75% / 8.50% Senior PIK Toggle Notes due 2022 INDENTURE Dated as of May 14, 2019 WILMINGTON TRUST, NATIONAL ASSOCIATION, as TrusteePPD, Inc. • January 16th, 2020 • Services-commercial physical & biological research • New York
INDENTURE, dated as of May 14, 2019, as amended or supplemented from time to time (this “Indenture”), between EAGLE HOLDING COMPANY II, LLC, a limited liability company organized under the laws of the State of Delaware (the “Issuer”), and WILMINGTON TRUST, NATIONAL ASSOCIATION, as trustee (in such capacity, the “Trustee”).
FORM OF INDEMNIFICATION AGREEMENTIndemnification Agreement • January 16th, 2020 • PPD, Inc. • Services-commercial physical & biological research • Delaware
This Indemnification Agreement is dated as of , 20 (this “Agreement”) and is between PPD, Inc. a Delaware corporation (the “Company”), and [name of director/officer] (“Indemnitee”).
JAGUAR HOLDING COMPANY II and PPD DEVELOPMENT, L.P. as Issuers 4.625% Senior Notes due 2025 5.000% Senior Notes due 2028 INDENTURE Dated as of June 5, 2020 WILMINGTON TRUST, NATIONAL ASSOCIATION, as TrusteePPD, Inc. • June 5th, 2020 • Services-commercial physical & biological research • New York
INDENTURE, dated as of June 5, 2020, as amended or supplemented from time to time (this “Indenture”), among JAGUAR HOLDING COMPANY II, a Delaware corporation ( “Jaguar”), PPD DEVELOPMENT, L.P., a Delaware limited partnership (the “Co-Issuer” and, together with Jaguar, the “Issuers”), the Guarantors (as defined herein) and WILMINGTON TRUST, NATIONAL ASSOCIATION, as trustee (in such capacity, the “Trustee”). The Issuers are subsidiaries of PPD, Inc., a Delaware corporation (the “Company”).
EAGLE HOLDING COMPANY I WILMINGTON, NORTH CAROLINA 28401 May 2, 2018PPD, Inc. • January 16th, 2020 • Services-commercial physical & biological research
Reference is made to (i) the Stockholders Agreement, dated as of May 11, 2017 (the “Stockholders Agreement”), by and among Eagle Holding Company I, a Delaware corporation (together with any successor, the “Company”), Carlyle Partners VI Holdings II, L.P., a Delaware limited partnership, Carlyle Partners VI, L.P., a Delaware limited partnership, CP VI Coinvestment A, L.P., a Delaware limited partnership, CP VI Coinvestment B, L.P., a Delaware limited partnership, Hellman & Friedman Capital Partners VII, L.P., a Cayman Islands limited partnership, Hellman & Friedman Capital Partners VII (Parallel), L.P., a Cayman Islands limited partnership, HFCP VII (Parallel-A), L.P., a Delaware limited partnership, and H&F Executives VII, L.P., a Cayman Islands limited partnership, Hellman & Friedman Capital Partners VIII, L.P., a Cayman Islands limited partnership, Hellman & Friedman Capital Partners VIII (Parallel), L.P., a Cayman Islands limited partnership, HFCP VIII (Parallel-A), L.P., a Delaware
EMPLOYMENT AGREEMENTEmployment Agreement • January 16th, 2020 • PPD, Inc. • Services-commercial physical & biological research • North Carolina
This Employment Agreement (this “Agreement”), dated as of April 10, 2012 (the “Effective Date”), is made by and between Pharmaceutical Product Development, LLC, a Delaware limited liability company (together with any successor thereto, the “Company”), and B. Judd Hartman (the “Executive” and, together with the Company, the “Parties”) and, solely with respect to Section 9(n), Jaguar Holding Company I, a Delaware corporation (“Parent”). Where the context requires, references herein to the “Company” include Pharmaceutical Product Development, Inc., a North Carolina corporation and predecessor to the Company.
EAGLE HOLDING COMPANY I STOCK OPTION AGREEMENT GRANT NOTICEStock Option Agreement • January 16th, 2020 • PPD, Inc. • Services-commercial physical & biological research
Unless otherwise defined herein, the terms defined in the Eagle Holding Company I 2017 Equity Incentive Plan, as the same has been or may be amended from time to time in accordance therewith (the “Plan”), shall have the same defined meanings in this Stock Option Agreement, which includes the terms in this Grant Notice (the “Grant Notice”), Appendix A attached hereto, and Appendix B attached hereto (collectively, the “Agreement”).
ASSIGNMENT AND ASSUMPTION AGREEMENTAssignment and Assumption Agreement • January 16th, 2020 • PPD, Inc. • Services-commercial physical & biological research • North Carolina
THIS ASSIGNMENT AND ASSUMPTION AGREEMENT (this “Agreement”), dated as of May 11, 2017, is entered into by and among Jaguar Holding Company I, a Delaware corporation (the “Assignor”), Eagle Holding Company I, a Delaware corporation (the “Assignee”), Pharmaceutical Product Development, LLC, a Delaware limited liability company (“PPD”) and William Sharbaugh (the “Executive”). Capitalized or other terms used and not defined herein shall have the meanings ascribed to them in that certain Agreement and Plan of Merger, dated as of April 26, 2017 (as amended, restated, modified or supplemented from time to time, the “Merger Agreement”), by and among the Assignee, Eagle Holding Company II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Assignee (“Holdings”), Eagle Reorganization Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Holdings, Eagle Buyer, Inc., a Delaware corporation and the Assignor.
AMENDED AND RESTATED CONSULTING SERVICES AGREEMENTConsulting Services Agreement • January 16th, 2020 • PPD, Inc. • Services-commercial physical & biological research • Delaware
This Amended and Restated Consulting Services Agreement (this “Agreement”), dated as of May 11, 2017, by and between PPD Development, L.P., a Delaware limited partnership (the “Company”), Hellman & Friedman LP, a Delaware limited partnership (“Consultant”), and, solely for purposes of Section 1(a), Jaguar Holding Company I, a Delaware corporation (“Jaguar I”).
SECOND AMENDED AND RESTATED STOCKHOLDERS AGREEMENT AMONG PPD, INC. AND THE STOCKHOLDERS AS DEFINED HEREIN February 10, 2020Stockholders Agreement • February 11th, 2020 • PPD, Inc. • Services-commercial physical & biological research • Delaware
This SECOND AMENDED AND RESTATED STOCKHOLDERS AGREEMENT, dated as of February 10, 2020, is by and among (i) PPD, Inc., a Delaware corporation (together with its successors and assigns, the “Company”); (ii) Carlyle Partners VI Holdings II, L.P., a Delaware limited partnership (“CP VI Holdings”), Carlyle Partners VI, L.P., a Delaware limited partnership (“Carlyle VI”), CP VI Coinvestment A, L.P., a Delaware limited partnership (“CP VI Coinvestment A”), CP VI Coinvestment B, L.P., a Delaware limited partnership (“CP VI Coinvestment B” and, together with Carlyle VI and CP VI Coinvestment A, the “Initial Carlyle Entities”); (iii) Hellman & Friedman Capital Partners VII, L.P., a Cayman Islands limited partnership (“HFCP VII”), Hellman & Friedman Capital Partners VII (Parallel), L.P., a Cayman Islands limited partnership (“HFCP VII Parallel”), HFCP VII (Parallel-A), L.P., a Delaware limited partnership (“HFCP VII Parallel-A”), H&F Executives VII, L.P., a Cayman Islands limited partnership (“H
HOLDINGS GUARANTY Dated as of August 18, 2015 between JAGUAR HOLDING COMPANY I, as Guarantor and CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, as Administrative AgentHoldings Guaranty • January 16th, 2020 • PPD, Inc. • Services-commercial physical & biological research • New York
HOLDINGS GUARANTY dated as of August 18, 2015 (as amended, modified, restated and/or supplemented from time to time, this “Guaranty”) between JAGUAR HOLDING COMPANY I, a Delaware corporation (the “Guarantor”), and CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, as administrative agent (in such capacity together with any successor administrative agent, the “Administrative Agent”) for the benefit of the Secured Parties (as defined in the Credit Agreement referred to below).
JAGUAR HOLDING COMPANY II and PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC as Issuers 6.375% Senior Notes due 2023 INDENTURE Dated as of August 18, 2015 WILMINGTON TRUST, NATIONAL ASSOCIATION, as TrusteePPD, Inc. • January 16th, 2020 • Services-commercial physical & biological research • New York
INDENTURE, dated as of August 18, 2015, as amended or supplemented from time to time (this “Indenture”), among JAGUAR HOLDING COMPANY II, a Delaware corporation (the “ Company”), PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC, a Delaware limited liability company (“PPD” and, together with the Company, the “Issuers”), the Guarantors (as defined herein) and WILMINGTON TRUST, NATIONAL ASSOCIATION, as trustee (in such capacity, the “Trustee”).
SUBSIDIARY GUARANTY Dated as of August 18, 2015 among THE GUARANTORS NAMED HEREIN and THE ADDITIONAL GUARANTORS REFERRED TO HEREIN, as Guarantors, and CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, as Administrative Agent and Collateral AgentSubsidiary Guaranty • January 16th, 2020 • PPD, Inc. • Services-commercial physical & biological research • New York
SUBSIDIARY GUARANTY dated as of August 18, 2015 (as amended, modified, restated and/or supplemented from time to time, this “Guaranty”) among the Persons listed on the signature pages hereof and the Additional Guarantors (as defined in Section 8) (such Persons so listed and the Additional Guarantors being, collectively, the “Guarantors” and, individually, each a “Guarantor”) in favor of Credit Suisse AG, Cayman Islands Branch, as administrative agent (in such capacity together with any successor administrative agent, the “Administrative Agent”) and collateral agent (in such capacity together with any successor collateral agent, the “Collateral Agent”) for the benefit of the Secured Parties (as defined in the Credit Agreement referred to below).
AGREEMENT AND PLAN OF MERGER dated as of April 26, 2017 by and among Eagle Holding Company I Eagle Holding Company II, LLC EAGLE REORGANIZATION MERGER SUB, INC. EAGLE BUYER, INC. and JAGUAR HOLDING COMPANY IAgreement and Plan of Merger • February 26th, 2021 • PPD, Inc. • Services-commercial physical & biological research • Delaware
This Agreement and Plan of Merger (this “Agreement”), dated as of April 26, 2017, is entered into by and among Eagle Holding Company I, a Delaware corporation (“Parent”), Eagle Holding Company II, LLC, a Delaware limited liability company and wholly owned subsidiary of Parent (“Holdings”), Eagle Reorganization Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Holdings (“Merger Sub”), Eagle Buyer, Inc., a Delaware corporation (“Buyer”), and Jaguar Holding Company I, a Delaware corporation (together with its successors and assigns, the “Company”).
EAGLE HOLDING COMPANY I WILMINGTON, NORTH CAROLINA 28401 May 11, 2017PPD, Inc. • February 26th, 2021 • Services-commercial physical & biological research
Reference is made to (i) the Stockholders Agreement, dated as of May 11, 2017 (the "Stockholders Agreement"), by and among Eagle Holding Company I, a Delaware corporation (together with any successor, the "Company"), Carlyle Partners VI Holdings II, L.P., a Delaware limited partnership, Carlyle Partners VI, L.P., a Delaware limited partnership, CP VI Coinvestment A, L.P., a Delaware limited partnership, CP VI Coinvestment B, L.P., a Delaware limited partnership, Hellman & Friedman Capital Partners VII, L.P., a Cayman Islands limited partnership, Hellman & Friedman Capital Partners VII (Parallel), L.P., a Cayman Islands limited partnership, HFCP VII (Parallel-A), L.P., a Delaware limited partnership, and H&F Executives VII, L.P., a Cayman Islands limited partnership, Hellman & Friedman Capital Partners VIII, L.P., a Cayman Islands limited partnership, Hellman & Friedman Capital Partners VIII (Parallel), L.P., a Cayman Islands limited partnership, HFCP VIII (Parallel-A), L.P., a Delaware
EMPLOYMENT AGREEMENTEmployment Agreement • February 26th, 2021 • PPD, Inc. • Services-commercial physical & biological research • North Carolina
This Employment Agreement (this "Agreement"), dated as of the 22nd day of May, 2013 (the "Effective Date"), is made by and between Pharmaceutical Product Development, LLC, a Delaware limited liability company (together with any successor thereto, the "Company"), and David Johnston (the "Executive" and, together with the Company, the "Parties") and, solely with respect to Section 9(n), Jaguar Holding Company I, a Delaware corporation ("Parent").
ASSIGNMENT AND ASSUMPTION AGREEMENTAssignment and Assumption Agreement • February 26th, 2021 • PPD, Inc. • Services-commercial physical & biological research • North Carolina
THIS ASSIGNMENT AND ASSUMPTION AGREEMENT (this "Agreement"), dated as of May 11, 2017, is entered into by and among Jaguar Holding Company I, a Delaware corporation (the "Assignor"), Eagle Holding Company I, a Delaware corporation (the "Assignee"), Pharmaceutical Product Development, LLC, a Delaware limited liability company ("PPD") and David M. Johnston (the "Executive"). Capitalized or other terms used and not defined herein shall have the meanings ascribed to them in that certain Agreement and Plan of Merger, dated as of April 26, 2017 (as amended, restated, modified or supplemented from time to time, the "Merger Agreement"), by and among the Assignee, Eagle Holding Company II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Assignee ("Holdings"), Eagle Reorganization Merger Sub, Inc., a Delaware corporation and wholly- owned subsidiary of Holdings, Eagle Buyer, Inc., a Delaware corporation and the Assignor.
AMENDMENT NO. 3 TO EMPLOYMENT AGREEMENTEmployment Agreement • February 26th, 2021 • PPD, Inc. • Services-commercial physical & biological research
THIS AMENDMENT NO. 3 TO EMPLOYMENT AGREEMENT (the “Amendment No. 3”), made and entered into this 23 day of February, 2021 and shall be effective as of February 1, 2021 (the “Effective Date”), by and between Pharmaceutical Product Development, LLC, a Delaware limited liability company (the “Company”), and David M. Johnston (the “Executive”).
JOINT FILING AGREEMENT PURSUANT TO RULE 13D-1(K)(1)Joint Filing Agreement • October 18th, 2021 • PPD, Inc. • Services-commercial physical & biological research
The undersigned acknowledge and agree that the Statement on Schedule 13D filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the shares of Common Stock, par value $0.0001 per share, of Science 37 Holdings, Inc. is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D shall be filed on behalf of each of the undersigned that is named as a reporting person in such filing without the necessity of filing an additional joint filing agreement. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that it knows or has reason to believe that such information is inaccurate. This joint filing a
AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENTEmployment Agreement • January 16th, 2020 • PPD, Inc. • Services-commercial physical & biological research
THIS AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT (the “Amendment No. 1”), made and entered into this 1st day of April, 2018 (the “Effective Date”) by and between Pharmaceutical Product Development, LLC, a Delaware limited liability company and successor to Pharmaceutical Product Development, Inc. (the “Company”), and David S. Simmons (the “Executive”).
EMPLOYMENT AGREEMENTEmployment Agreement • January 16th, 2020 • PPD, Inc. • Services-commercial physical & biological research • North Carolina
This Employment Agreement (this “Agreement”), dated as of May 17, 2012 (the “Effective Date”), is made by and among Pharmaceutical Product Development, LLC, a Delaware limited liability company (together with any successor or permitted assigns thereto, the “Company”), Jaguar Holding Company I, a Delaware corporation (together with any successor thereto, “Parent”) and David Simmons (the “Executive” and, together with the Parent and the Company, the “Parties”).
ContractCredit Agreement • January 16th, 2020 • PPD, Inc. • Services-commercial physical & biological research
AMENDMENT NO. 5 dated as of April 23, 2019 (this “Amendment”), to the CREDIT AGREEMENT dated as of August 18, 2015, as amended by that certain Amendment No. 1 dated as of May 31, 2016, that certain Amendment No. 2 dated as of November 10, 2016, that certain Amendment No. 3 dated as of May 30, 2017 and that certain Amendment No. 4 dated as of March 29, 2018 (the “Credit Agreement”), among JAGUAR HOLDING COMPANY II, a Delaware corporation (the “Parent Borrower”), PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC, a Delaware limited liability company (the “Subsidiary Borrower” and together with the Parent Borrower, the “Borrowers”), JAGUAR HOLDING COMPANY I, LLC (f/k/a JAGUAR HOLDING COMPANY I), a Delaware limited liability company (“Holdings”), each lender from time to time party thereto (collectively, the “Lenders” and, individually, a “Lender”), and CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, as Administrative Agent (in such capacity, the “Administrative Agent”), Collateral Agent (in such capacity,
ContractCredit Agreement • January 16th, 2020 • PPD, Inc. • Services-commercial physical & biological research
AMENDMENT NO. 3 dated as of May 30, 2017 (this “Amendment”), to the CREDIT AGREEMENT dated as of August 18, 2015, as amended by that certain Amendment No. 1, dated as of May 31, 2016 and that certain Amendment No. 2, dated as of November 10, 2016 (the “Credit Agreement”), among JAGUAR HOLDING COMPANY II, a Delaware corporation (the “Parent Borrower”), PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC, a Delaware limited liability company (the “Subsidiary Borrower” and together with the Parent Borrower, the “Borrowers”), JAGUAR HOLDING COMPANY I, LLC (f/k/a JAGUAR HOLDING COMPANY I), a Delaware limited liability company (“Holdings”), each lender from time to time party thereto (collectively, the “Lenders” and, individually, a “Lender”), and CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, as Administrative Agent (in such capacity, the “Administrative Agent”), Collateral Agent (in such capacity, the “Collateral Agent”) and L/C Issuer.
AMENDMENT NO. 2 TO EMPLOYMENT AGREEMENTEmployment Agreement • January 16th, 2020 • PPD, Inc. • Services-commercial physical & biological research
THIS AMENDMENT NO. 2 TO EMPLOYMENT AGREEMENT (the “Amendment No. 2”), made and entered into this 1st day of March, 2019 (the “Effective Date”) by and between Pharmaceutical Product Development, LLC, a Delaware limited liability company and successor to Pharmaceutical Product Development, Inc. (the “Company”), and William J. Sharbaugh (the “Executive”).
ContractCredit Agreement • January 16th, 2020 • PPD, Inc. • Services-commercial physical & biological research
AMENDMENT NO. 4 dated as of March 29, 2018 (this “Amendment”), to the CREDIT AGREEMENT dated as of August 18, 2015, as amended by that certain Amendment No. 1, dated as of May 31, 2016, that certain Amendment No. 2, dated as of November 10, 2016 and that certain Amendment No. 3 dated as of May 30, 2017 (the “Credit Agreement”), among JAGUAR HOLDING COMPANY II, a Delaware corporation (the “Parent Borrower”), PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC, a Delaware limited liability company (the “Subsidiary Borrower” and together with the Parent Borrower, the “Borrowers”), JAGUAR HOLDING COMPANY I, LLC (f/k/a JAGUAR HOLDING COMPANY I), a Delaware limited liability company (“Holdings”), each lender from time to time party thereto (collectively, the “Lenders” and, individually, a “Lender”), and CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, as Administrative Agent (in such capacity, the “Administrative Agent”), Collateral Agent (in such capacity, the “Collateral Agent”) and L/C Issuer.
AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENTEmployment Agreement • January 16th, 2020 • PPD, Inc. • Services-commercial physical & biological research
THIS AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT (the “Amendment No. 1”), made and entered into this 10th day of February, 2016 (the “Effective Date”) by and between Pharmaceutical Product Development, LLC, a Delaware limited liability company and successor to Pharmaceutical Product Development, Inc. (the “Company”), and B. Judd Hartman (the “Executive”).
PPD, Inc.PPD, Inc. • July 29th, 2021 • Services-commercial physical & biological research
Reference is made to that certain Agreement and Plan of Merger, dated as of April 26, 2017, by and among Eagle Holding Company I, Eagle Holding Company II, LLC, Eagle Reorganization Merger Sub, Inc., Eagle Buyer, Inc. and Jaguar Holding Company I (the “Specified Agreement”). Capitalized terms used in this letter agreement but not defined shall have the meanings ascribed thereto in the Specified Agreement.
CREDIT AGREEMENT DATED AS OF JANUARY 13, 2021 AMONG PPD, INC., AS BORROWER, PPD DEVELOPMENT, L.P., AS CO-BORROWER, JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT, COLLATERAL AGENT AND A L/C ISSUER, THE OTHER LENDERS AND L/C ISSUERS PARTY HERETO,...Credit Agreement • January 14th, 2021 • PPD, Inc. • Services-commercial physical & biological research • New York
This CREDIT AGREEMENT is entered into as of January 13, 2021, among PPD, INC., a Delaware corporation (the “Borrower”), PPD DEVELOPMENT, L.P., a Delaware limited partnership (the “Co-Borrower”), each lender from time to time party hereto (collectively, the “Lenders” and individually, a “Lender”), each L/C Issuer party hereto , and JPMORGAN CHASE BANK, N.A., as Administrative Agent, Collateral Agent and a L/C Issuer.
AMENDMENT NO. 2 TO EMPLOYMENT AGREEMENTEmployment Agreement • February 26th, 2021 • PPD, Inc. • Services-commercial physical & biological research
THIS AMENDMENT NO. 2 TO EMPLOYMENT AGREEMENT (the “Amendment No. 2”), made and entered into this 1st day of April, 2018 (the “Effective Date”) by and between Pharmaceutical Product Development, LLC, a Delaware limited liability company and successor to Pharmaceutical Product Development, Inc. (the “Company”), and David M. Johnston (the “Executive”).
EAGLE HOLDING COMPANY I STOCK OPTION AGREEMENT GRANT NOTICEStock Option Agreement • January 16th, 2020 • PPD, Inc. • Services-commercial physical & biological research
Unless otherwise defined herein, the terms defined in the Eagle Holding Company I 2017 Equity Incentive Plan, as the same has been or may be amended from time to time in accordance therewith (the “Plan”) shall have the same defined meanings in this Stock Option Agreement, which includes the terms in this Grant Notice (the “Grant Notice”), Appendix A attached hereto, and Appendix B attached hereto (collectively, the “Agreement”).
ASSIGNMENT AND ASSUMPTION AGREEMENTAssignment and Assumption Agreement • January 16th, 2020 • PPD, Inc. • Services-commercial physical & biological research • North Carolina
THIS ASSIGNMENT AND ASSUMPTION AGREEMENT (this “Agreement”), dated as of May 11, 2017, is entered into by and among Jaguar Holding Company I, a Delaware corporation (the “Assignor”), Eagle Holding Company I, a Delaware corporation (the “Assignee”), Pharmaceutical Product Development, LLC, a Delaware limited liability company (“PPD”) and David Simmons (the “Executive”). Capitalized or other terms used and not defined herein shall have the meanings ascribed to them in that certain Agreement and Plan of Merger, dated as of April 26, 2017 (as amended, restated, modified or supplemented from time to time, the “Merger Agreement”), by and among the Assignee, Eagle Holding Company II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Assignee (“Holdings”), Eagle Reorganization Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Holdings, Eagle Buyer, Inc., a Delaware corporation and the Assignor.
AMENDMENT NO. 3 TO EMPLOYMENT AGREEMENTEmployment Agreement • January 16th, 2020 • PPD, Inc. • Services-commercial physical & biological research
THIS AMENDMENT NO. 3 TO EMPLOYMENT AGREEMENT (the “Amendment No. 3”), made and entered into this 18th day of December, 2019 (the “Effective Date”) by and between Pharmaceutical Product Development, LLC, a Delaware limited liability company and successor to Pharmaceutical Product Development, Inc. (the “Company”), and B. Judd Hartman (the “Executive”).
